SCHEMBL10189784

SCHEMBL10189784

Cc1cc(-c2nn[nH]c2-c2ccc(-c3nnnn3C)cc2)cc2c1OCO2

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.33
HPGD P15428 4/20 0.33
KDM4E B2RXH2 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
HTT P42858 2/20 0.33
MAPT P10636 2/20 0.33
LMNA P02545 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
USP2 O75604 2/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HSD11B1 P28845 1/20 0.32
PTGS2 P35354 1/20 0.32
NPSR1 Q6W5P4 3/20 0.32
GAA P10253 1/20 0.32
PAX8 Q06710 1/20 0.32
PIP4K2C Q8TBX8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
MAPK1 P28482 1/20 0.31
MAP2K4 P45985 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL410895 0.88 ALDH1A1 (0.46) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL10189782 0.83 ALDH1A1 (0.35) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL10189779 0.82 MAPK1 (0.34) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL10189775 0.81 MAPT (0.34) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL10189783 0.80 HSD11B1 (0.38) MEN1KMT2AHSD11B1RAB9A
SCHEMBL10189758 0.79 PTGS2 (0.31) PTGS2MAPK1MAP2K4MAPKAPK2MAPKAPK3
SCHEMBL10189759 0.78 LMNA (0.37) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL10189778 0.77 BRD4 (0.32) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL10189757 0.76 MAPK1 (0.33) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL10189780 0.76 MEN1 (0.36) ALDH1A1HPGDKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 ALDH1A1 1872/4885HPGD 3241/4885KDM4E 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.